For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

Before collapsing, he recently learned that he had the gene for something called Brugada syndrome. Years earlier, his brother was diagnosed with it after collapsing several times while playing ...

Disease name: Trimethylaminuria (TMAU), also known as "fish odor syndrome" Affected populations: TMAU is a rare metabolic condition that causes a person to smell like rotten fish. The condition is ...

On Wall Street and in C-suites across the country, titans of American industry and capital are aghast. How could President Donald Trump plunge us into ruinous trade wars amid yo-yoing tariffs and ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...

The disorder is called CerTra syndrome, and it is not hereditary. People with CerTra syndrome have developmental delays, seizures, traits similar to autism, visual and hearing differences ...

The Food and Drug Administration approved a medication this week known as VYKAT XR to treat hyperphagia — or an incessant feeling of hunger — in kids and adults with Prader-Willi syndrome. The ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...

March 27, 2025 – The FDA has approved a drug to treat a key symptom of a rare life-threatening genetic disorder known as Prader-Willi syndrome (PWS) in adults and children ages 4 or older.

The FDA has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets to treat hyperphagia in individuals aged four years and older with Prader-Willi syndrome (PWS). The ...

ADHD and Tourette's syndrome are two separate conditions, but they have a few things in common. They often start around the same age, and in some cases children can have both conditions.

Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for Prader-Willi syndrome (PWS), a rare genetic disorder that causes excessive appetite and obesity. Vykat XR (diazoxide ...